The news on Bristol Myers Squibb
ShareThere has been 18 news on Bristol Myers Squibb in the past from 6 different sources and amongst 2 sections.
Full access to all news in this scope:
See the trend on this scope:
Evolution through time
Latest news
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
Judge tosses Medicare drug negotiation challenges from Bristol Myers Squibb, Johnson & Johnson
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb drafts contingency plans for US restrictions on Chinese pharma
Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
J&J, Merck and Bristol Myers Squibb CEOs Defend Drug Prices at Senate Hearing
J&J, Merck and Bristol Myers CEOs defend high drug prices in Senate hearing, as Biden tries to cut costs
Bristol Myers Squibb results top estimates as new drugs post strong sales growth
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
Stocks making the biggest moves midday: Nike, Rocket Lab, Bristol Myers, NetEase and more
Stocks making the biggest moves before the bell: Nike, Bristol Myers, NetEase, Coinbase, and more
Bristol Myers Squibb to Discontinue Metastatic Colorectal Cancer Trial
Bristol Myers to Buy Mirati Therapeutics for $4.8 Billion
Sections
The coverage spreads amongst 2 sections:
Sources
There has been 6 news sources reporting on this, including: CNBC News (67%), The Wall Street Journal (11%), The Hill (6%), Financial Times (6%), The New York Times (6%).
Going further
Stay up to date:
Details
This content can be used under the CC BY 4.0 license
